Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib

INTRODUCTION: Lorlatinib (LOR) or pemetrexed-based chemotherapy (PEM) is the standard treatment after failure of a second-generation ALK tyrosine kinase inhibitor, such as alectinib, in patients with ALK-positive NSCLC. Nevertheless, there have been few data on the clinical outcomes of these treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeyasu, Yuki, Yoshida, Tatsuya, Masuda, Ken, Matsumoto, Yuji, Shinno, Yuki, Okuma, Yusuke, Goto, Yasushi, Horinouchi, Hidehito, Yamamoto, Noboru, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046446/
https://www.ncbi.nlm.nih.gov/pubmed/35498380
http://dx.doi.org/10.1016/j.jtocrr.2022.100311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046446/
https://www.ncbi.nlm.nih.gov/pubmed/35498380
http://dx.doi.org/10.1016/j.jtocrr.2022.100311

Ejemplares similares